{
    "id": "3468e009-cfd1-f217-e063-6294a90a1429",
    "indications": {
        "text": "zanaflex indicated management spasticity . short duration therapeutic effect , treatment zanaflex reserved daily activities times relief spasticity important [ ( 2.1 ) ] .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "recommended starting dose : 2 mg ; dose repeated 6 8 hour intervals , maximum 3 doses 24 hours ( 2.1 ) increased 2 mg 4 mg per dose , 1 4 days increases ; total daily dose exceed 36 mg ( 2.1 ) tizanidine pharmacokinetics differs tablets capsules , taken without food . differences could result change tolerability control symptoms ( 2.1 , 12.3 ) discontinue zanaflex , decrease dose slowly minimize risk withdrawal rebound hypertension , tachycardia , hypertonia ( 2.2 )",
        "doid_entities": [
            {
                "text": "hypertension (DOID:10763)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10763"
            }
        ],
        "orphanet_entities": []
    },
    "adverseReactions": "zanaflex contraindicated patients taking potent inhibitors cyp1a2 , fluvoxamine ciprofloxacin [ ( 7.1 , 7.2 ) ] .",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "TIZANIDINE HYDROCHLORIDE",
            "code": "B53E3NMY5C",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9609"
        },
        {
            "name": "STEARIC ACID",
            "code": "4ELV7Z65AP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        }
    ],
    "organization": "Covis Pharma US, Inc",
    "name": "Zanaflex",
    "effectiveTime": "20250505",
    "indications_original": "Zanaflex is indicated for the management of spasticity. Because of the short duration of therapeutic effect, treatment with Zanaflex should be reserved for those daily activities and times when relief of spasticity is most important\n \n  [see Dosage and Administration (\n  \n   2.1)]\n \n  .",
    "contraindications_original": "Recommended starting dose: 2 mg; dose can be repeated at 6 to 8 hour intervals, up to a maximum of 3 doses in 24 hours ( 2.1 ) Dosage can be increased by 2 mg to 4 mg per dose, with 1 to 4 days between increases; total daily dose should not exceed 36 mg ( 2.1 ) Tizanidine pharmacokinetics differs between tablets and capsules, and when taken with or without food. These differences could result in a change in tolerability and control of symptoms ( 2.1 , 12.3 ) To discontinue Zanaflex, decrease dose slowly to minimize the risk of withdrawal and rebound hypertension, tachycardia, and hypertonia ( 2.2 )",
    "adverseReactions_original": "Zanaflex is contraindicated in patients taking potent inhibitors of CYP1A2, such as fluvoxamine or ciprofloxacin\n \n  [see Drug Interactions (\n  \n   7.1,\n  \n   7.2)]\n \n  .",
    "drug": [
        {
            "name": "Zanaflex",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        }
    ]
}